Literature DB >> 12949533

Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues.

Katayoon Goodarzi1, Mahmoud Goodarzi, Andrew M Tager, Andrew D Luster, Ulrich H von Andrian.   

Abstract

Leukotriene B4 (LTB4) is a potent chemoattractant for myeloid leukocytes, which express BLT1, the high-affinity receptor for LTB4. We report here that BLT1 is induced substantially in CD8+ effector T cells and at lower amounts in CD8+ central memory T cells. LTB4 elicited BLT1-dependent chemotaxis in effector cells, but not in naive or central memory cells. Intravital microscopy showed that BLT1 signaling induced rapid integrin-mediated arrest of rolling effector and central memory cells in postcapillary venules. In competitive homing experiments, wild-type effector cells were three times more efficient at migrating to the inflamed peritoneal cavity than were BLT-deficient effector cells. These results identify LTB4-BLT1 as a potent nonchemokine pathway for cytotoxic effector cell traffic.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12949533     DOI: 10.1038/ni972

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  90 in total

1.  The membrane organization of leukotriene synthesis.

Authors:  Asim K Mandal; Jesse Skoch; Brian J Bacskai; Bradley T Hyman; Peter Christmas; Douglas Miller; Ting-ting D Yamin; Shihua Xu; Douglas Wisniewski; Jilly F Evans; Roy J Soberman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-14       Impact factor: 11.205

2.  Blocking the leukotriene B4 receptor 1 inhibits late-phase airway responses in established disease.

Authors:  Koichi Waseda; Nobuaki Miyahara; Arihiko Kanehiro; Genyo Ikeda; Hikari Koga; Yasuko Fuchimoto; Etsuko Kurimoto; Yasushi Tanimoto; Mikio Kataoka; Mitsune Tanimoto; Erwin W Gelfand
Journal:  Am J Respir Cell Mol Biol       Date:  2011-03-18       Impact factor: 6.914

Review 3.  Regulation of immunity by lysosphingolipids and their G protein-coupled receptors.

Authors:  Edward J Goetzl; Hugh Rosen
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

Review 4.  Mast cell survival and activation by IgE in the absence of antigen: a consideration of the biologic mechanisms and relevance.

Authors:  Toshiaki Kawakami; Jiro Kitaura
Journal:  J Immunol       Date:  2005-10-01       Impact factor: 5.422

5.  Differential induction of BLT receptor expression on human endothelial cells by lipopolysaccharide, cytokines, and leukotriene B4.

Authors:  Hong Qiu; Anne-Sofie Johansson; Mattias Sjöström; Min Wan; Oliver Schröder; Jan Palmblad; Jesper Z Haeggström
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-19       Impact factor: 11.205

Review 6.  In vivo imaging of the immune response in the eye.

Authors:  Doran B Spencer; Ellen J Lee; Tatsushi Kawaguchi; James T Rosenbaum
Journal:  Semin Immunopathol       Date:  2008-03-05       Impact factor: 9.623

7.  Adipose tissue B2 cells promote insulin resistance through leukotriene LTB4/LTB4R1 signaling.

Authors:  Wei Ying; Joshua Wollam; Jachelle M Ofrecio; Gautam Bandyopadhyay; Dalila El Ouarrat; Yun Sok Lee; Da Young Oh; Pingping Li; Olivia Osborn; Jerrold M Olefsky
Journal:  J Clin Invest       Date:  2017-02-13       Impact factor: 14.808

8.  Lipid mediator metabolic profiling demonstrates differences in eicosanoid patterns in two phenotypically distinct mast cell populations.

Authors:  Susanna L Lundström; Rohit Saluja; Mikael Adner; Jesper Z Haeggström; Gunnar Nilsson; Craig E Wheelock
Journal:  J Lipid Res       Date:  2012-10-03       Impact factor: 5.922

Review 9.  Leukotriene receptors as potential therapeutic targets.

Authors:  Takehiko Yokomizo; Motonao Nakamura; Takao Shimizu
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

10.  Leukotriene B4-driven neutrophil recruitment to the skin is essential for allergic skin inflammation.

Authors:  Michiko K Oyoshi; Rui He; Yitang Li; Subhanjan Mondal; Juhan Yoon; Roshi Afshar; Mei Chen; David M Lee; Hongbo R Luo; Andrew D Luster; John S Cho; Lloyd S Miller; Allison Larson; George F Murphy; Raif S Geha
Journal:  Immunity       Date:  2012-10-11       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.